Skip to main content
Uncategorized

Barcelona Science Park to house the Biomed Division of LEITAT

By 28 de May de 2008November 18th, 2020No Comments
< Back to news
 28.05.2008

Barcelona Science Park to house the Biomed Division of LEITAT

The Minister for Innovation, Universities and Enterprise, Josep Huguet, the president of the LEITAT Technological Centre, Eusebi Cima, and the director general of the Barcelona Science Park, Fernando Albericio, today joined forces to present the new biomedical division of LEITAT in the Barcelona Science Park. The unit, which goes by the name of Biomed Division, will work particularly in the area of oncology research and is formed by a group of eight scientists, all of whom used to work at the bioresearch laboratory which the multinational pharmaceutical firm Merck had operated on the Park premises prior to its closure at the end of last year.


The new unit will be based within the Barcelona Science Park, a setting that offers an ideal platform for developing synergies with other prestigious and internationally-recognised research groups, as well as enabling the use and incorporation of the state-of-the-art technology which is available as part of the extensive research support services offered by the Park.

The creation of this new division has been possible thanks to the coming together of three key factors: the desire of a group of former Merck employees to set up their own business, taking advantage of their extensive experience in the field of oncology research within a multinational pharmaceutical firm; the commitment on the part of LEITAT to diversify its activities and create a new knowledge unit within the field of biomedical research; and the support of the Catalan government through its commitment to boosting research and innovation.

The basic objective of the new LEITAT division is to identify new molecular targets and new drugs in the treatment of cancer. A further aim is to offer a wide range of services to the pharmaceutical industry and related companies in order to analyse the anticancer activity of new compounds and/or identify new indications in the field of known oncology compounds. In addition, the division will seek to establish collaborative projects with both public and private health organisations and biomedical research institutions, the aim being to improve upon existing protocols in the treatment of cancer.